Diagnosing and Treating MPNs

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.

Kristie L. Kahl

Exploring New Therapies and Sequencing in Relapsed CLL

Ariana Pelosci

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

Morgan Bayer

SELECT-MDS-1 Trial of Tamibarotene Misses Primary End Point in MDS

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Balancing Clinical Data and Real-World Insights in CML Treatment

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for high-risk myelodysplastic syndrome, leading to the trial being discontinued.

FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.

Related Content

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Kristie L. Kahl

Exploring New Therapies and Sequencing in Relapsed CLL

Ariana Pelosci

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

Morgan Bayer

SELECT-MDS-1 Trial of Tamibarotene Misses Primary End Point in MDS

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Balancing Clinical Data and Real-World Insights in CML Treatment

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for high-risk myelodysplastic syndrome, leading to the trial being discontinued.